David M. Rubenstein Center for Pancreatic Cancer Research

Memorial Sloan Kettering’s David M. Rubenstein Center for Pancreatic Cancer Research, established in 2014 with generous support from David M. Rubenstein, aims to improve the lives of patients with pancreatic malignancies through bold, innovative, multidisciplinary research. This pursuit is urgent, as pancreatic cancer is currently the fourth leading cause of cancer death in the United States and is expected to become the second leading cause by 2020. Members of the Rubenstein Center are working collaboratively to make pancreatic cancer a more manageable and potentially curable disease. Led by an internationally renowned team of clinicians and scientists, the Rubenstein Center has established the following strategic priorities:

  • Recruiting new faculty members whose research will focus entirely on pancreatic cancer
  • Providing enhanced education and support for pancreatic cancer patients and their families
  • Facilitating daily interactions between scientists and clinicians caring for pancreatic cancer patients
  • Expanding Memorial Sloan Kettering’s substantial portfolio of clinical trials for pancreatic cancer patients, including an enhanced effort to move the development of new drugs to phase 1 trials
  • Creating enabling infrastructure and resources to augment translational and clinical research on pancreatic cancer and foster collaborations within Memorial Sloan Kettering’s research community and beyond
  • Providing grant funding to support creative and innovative pancreatic cancer research, including outstanding projects that might be considered too exploratory or preliminary to be funded by traditional mechanisms
  • Training the next generation of pancreatic cancer investigators and clinicians

“I have been deeply impressed by the leadership Memorial Sloan Kettering has shown in its programs devoted to treating pancreatic cancer, and I am convinced that bringing clinicians, researchers, fellows, and other staff together in a comprehensive, highly unified effort offers the best hope for reducing the enormous toll that this terrible disease takes in terms of human life and suffering.”


More Information

Target ALS

Amyotrophic lateral sclerosis (ALS; aka Lou Gehrig’s disease) remains a terrible disease for patients and their families, and for doctors trying to help. The goal of Target ALS is to increase the number, robustness and intensity of ALS drug development programs in the pharma/biotech industry by supporting the best preclinical research and fostering interactions between academia and industry. Given our success in building this bridge over the past two years, our central strategy now is to validate novel therapeutic targets—molecular steps in the disease pathway which, when blocked by a drug, can slow or prevent disease progression—to be built upon by the industry.

Founding donors, Dan Doctoroff, David Rubenstein and Bloomberg Philanthropies provided 3-year funding of $25 million, which has been supplemented by more than $1 million from other anonymous donors. Increasingly, members of the public have expressed their wish to support this unique effort.

“With fresh resources and determined collaboration, we can make steady progress toward a cure for this devastating disease, Dan, Mike, and I hope these resources will serve as a unifying catalyst for the great work that is being done around the world to cure and prevent ALS.”


More Information

David M. Rubenstein Child Health Building

Johns Hopkins University trustee David Rubenstein a long-time patron of the institution, has gifted funds to support the new and only Hopkins outpatient facility exclusively devoted to children and adolescent health care. The building will be called the David M. Rubenstein Child Health Building at Johns Hopkins Children’s Center. The final phase of construction on the 90,000-square-foot structure was completed in December. It will house all primary care clinics for the young, as well as the historic Harriet Lane Clinic, which has a nearly century-long commitment to the care of poor, minority children. “As the landscape of our East Baltimore campus begins its rebirth, we are embarking on an exciting new era in Hopkins history,” says Edward D. Miller, M.D., Baker Dean and CEO of Johns Hopkins Medicine. “These advances wouldn’t be possible without the generosity of donors like David Rubenstein.”

“As a parent, I believe that every child deserves access to top-notch health care, and you can’t get any better than Johns Hopkins,” says Rubenstein. “That’s why I wanted to help support the mission of this building and the Johns Hopkins Children’s Center. Also, I wanted to help in this modest way the city in which I was born and raised and to which I owe so much.”

More Information

David M. Rubenstein Hearing Center, Johns Hopkins University School of Medicine

In 2015, David Rubenstein, a Johns Hopkins University and Johns Hopkins Medicine trustee, donated funds to the John Hopkins University School of Medicine, Department of Otolaryngology—Head and Neck Surgery to create a new hearing center focused on restoring functional hearing loss.

The patient care clinical space for the otology clinic at the Johns Hopkins Outpatient Center will be renamed the David M. Rubenstein Hearing Center. The center will include the Division of Otology and Neurotology, the Division of Audiology, and the Listening Center. The center will integrate clinical care and research to help restore functional hearing in people with congenital and acquired hearing loss. A key research area for the center will be “system-based” hearing restoration. Researchers will explore novel approaches to protect and repair the inner ear and to ensure effective connectivity with the brain.

“These promising areas of research will hopefully get us closer to helping people with hearing loss and deafness. The sense of hearing is a precious gift.”

More Information





©2022 DavidRubenstein.com LLC    All Rights Reserved

Site design by FCI Creative